SCHEMBL32690239

SCHEMBL32690239

COc1ccc(-n2nc(-c3ccc(C#N)c(F)c3)cc2C(=O)O)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 4/20 0.54
CYP11B2 P19099 4/20 0.54
ALDH1A1 P00352 2/20 0.50
LMNA P02545 2/20 0.50
HTT P42858 2/20 0.50
KDM1A O60341 3/20 0.44
TUBB4A P04350 1/20 0.42
TUBB P07437 1/20 0.42
TUBA3C P0DPH7 1/20 0.42
STAT3 P40763 1/20 0.42
TUBA1B P68363 1/20 0.42
TUBA4A P68366 1/20 0.42
TUBB4B P68371 1/20 0.42
TUBB3 Q13509 1/20 0.42
TUBB2A Q13885 1/20 0.42
TUBB8 Q3ZCM7 1/20 0.42
TUBA3E Q6PEY2 1/20 0.42
TUBA1A Q71U36 1/20 0.42
TUBA1C Q9BQE3 1/20 0.42
TUBB6 Q9BUF5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32690269 0.88 KMT2A (0.53) CYP11B1CYP11B2ALDH1A1LMNAKDM1A
SCHEMBL31467248 0.86 L3MBTL1 (0.42) CYP11B1CYP11B2KDM1APOLBRECQL
SCHEMBL32690329 0.84 HTT (0.57) ALDH1A1LMNAHTTNPC1MAPT
SCHEMBL30963718 0.83 KDM1A (0.43) CYP11B1CYP11B2ALDH1A1LMNAKDM1A
SCHEMBL32690404 0.81 RPA1 (0.64) CYP11B1CYP11B2SMN1; SMN2RPA1KMT2A
SCHEMBL32690295 0.81 KDM1A (0.67) KDM1A
SCHEMBL30963708 0.78 KDM1A (0.44) KDM1A
SCHEMBL1996485 0.77 ALDH1A1 (0.49) ALDH1A1LMNAHTTNPC1MAPT
SCHEMBL30963704 0.77 LMNA (0.44) CYP11B1CYP11B2LMNAKDM1AMAPT
SCHEMBL27420636 0.75 CYP11B1 (0.53) CYP11B1CYP11B2LMNAKDM1ATUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085082-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2026-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085082-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM5C CYP11B1 2949/4885CYP11B2 3493/4885ALDH1A1 1311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.